GlaxoSmithKline offers H1N1 vaccine update

GlaxoSmithKline has published an update detailing its activities so far regarding supplies of its H1N1 adjuvanted vaccine.

The company has been working to the guidelines of the World Health Organisation (WHO) since the June 2009 pandemic declaration and has supplied many governments with the product in accordance with their individual needs.

Around 130 million doses of the vaccine were shipped to various counties during the fourth quarter of 2009, bringing the amount the firm has earned from the product to approximately 835 million pounds.

In 2010, the company plans to open discussions with governments regarding their changing immunisation programmes and whether they require fewer or more orders of the vaccine over the coming months.

Furthermore, GlaxoSmithKline will donate 60 million doses of its vaccine to the WHO, which plans to distribute it among developing nations.

GlaxoSmithKline’s H1N1 vaccine was approved for marketing by the European commission at the beginning of October 2009 ahead of the winter flu season and an anticipated rise in outbreaks of the virus.